Cardiovascular Event Reduction and Adverse Events Among Subjects Attaining Low-Density Lipoprotein Cholesterol <50 mg/dl With Rosuvastatin
- 1 April 2011
- journal article
- research article
- Published by Elsevier in Journal of the American College of Cardiology
- Vol. 57 (16) , 1666-1675
- https://doi.org/10.1016/j.jacc.2010.09.082
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca LP
- AstraZeneca
- Novartis
- Merck
- Abbott
- Roche
- Sanofi-Aventis
This publication has 38 references indexed in Scilit:
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinNew England Journal of Medicine, 2008
- Low LDL-C Levels and CancerJournal of the American College of Cardiology, 2008
- Statins, Low-Density Lipoprotein Cholesterol, and Risk of CancerJournal of the American College of Cardiology, 2008
- Psychiatric Adverse Reactions with Statins, Fibrates and EzetimibeDrug Safety, 2007
- Serum cholesterol, haemorrhagic stroke, ischaemic stroke, and myocardial infarction: Korean national health system prospective cohort studyBMJ, 2006
- Advances in Understanding Drug-Induced NeuropathiesDrug Safety, 2006
- Can Low-Density Lipoprotein Be Too Low? The Safety and Efficacy of Achieving Very Low Low-Density Lipoprotein With Intensive Statin TherapyJournal of the American College of Cardiology, 2005
- Cardiovascular Disease Resulting From a Diet and Lifestyle at Odds With Our Paleolithic Genome: How to Become a 21st-Century Hunter-GathererMayo Clinic Proceedings, 2004
- Absence of effect of simvastatin on the progression of lens opacities in a randomised placebo controlled study. Oxford Cholesterol Study Group.British Journal of Ophthalmology, 1995
- Serum cholesterol and hemorrhagic stroke in the Honolulu Heart Program.Stroke, 1989